Amgen (AMGN) Wins Patent Appeal On Otezla

Go back to Amgen (AMGN) Wins Patent Appeal On Otezla

AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)

April 19, 2023 4:45 PM EDT

Appeals Court Affirms Validity of Patent Expiring in 2028

THOUSAND OAKS, Calif., April 19, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against... More